TL
TriSalus Life Sciences, Inc.
TLSI · NASDAQ
$5.10 +3.87% (+$0.19)
1M -0.20%
Market Cap $314.0M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.59
49.2% downside
Current Price
$5.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TLSI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
8 /100
Expensive P/S 6.97x
P/B 47.94x
P/E N/A
Growth
100 /100
Growing Rev. growth 53.85%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Gross margin 85.79%
FCF margin 66.34%
Net margin 62.59%
Quality
13 /100
Poor ROIC 59.25%
Asset turnover 0.72x
ROA 45.18%
Debt
23 /100
High Debt/Equity 5.26x
Int. coverage -3.83x
Current ratio 5.35x
Stability
57 /100
Moderate Beta 0.44x
Profitable years 0
Rev. volatility 4.86%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TLSI
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Mary T. Szela
Employees
102
Headquarters
Westminster
Upcoming events
12 NOV
Earnings
Upcoming earnings report